TY - JOUR
T1 - Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma
AU - Marrero, Jorge
AU - Maluccio, Mary A.
AU - McCurdy, Heather
AU - Abou-Alfa, Ghassan K.
PY - 2014/4
Y1 - 2014/4
N2 - Dr Marrero is a consultant with and serves on the advisory boards for Onyx Pharmaceuticals and Bayer. Dr Maluccio has no relevant financial relationships with commercial interests to disclose. Ms McCurdy is on the speakers' bureau for Onyx Pharmaceuticals. Dr Abou-Alfa and/or his spouse serve as a consultant for Aduro Biotech, Astellas Pharma US, AstraZeneca, Bayer, Celgene, Celsion, Eli Lilly and Company, Exelixis, Genentech, IntegraGen, Jennerex Biotherapeutics, MedImmune, Novartis, Pharmacyclics, Roche, sanofi-aventis, Silenseed, and Vicus Therapeutics. He and/or his spouse have received research grants from Abbott Laboratories, Amgen, Bayer, Eli Lilly and Company, Exelixis, Genentech, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, sanofi-aventis, and Vicus Therapeutics.
AB - Dr Marrero is a consultant with and serves on the advisory boards for Onyx Pharmaceuticals and Bayer. Dr Maluccio has no relevant financial relationships with commercial interests to disclose. Ms McCurdy is on the speakers' bureau for Onyx Pharmaceuticals. Dr Abou-Alfa and/or his spouse serve as a consultant for Aduro Biotech, Astellas Pharma US, AstraZeneca, Bayer, Celgene, Celsion, Eli Lilly and Company, Exelixis, Genentech, IntegraGen, Jennerex Biotherapeutics, MedImmune, Novartis, Pharmacyclics, Roche, sanofi-aventis, Silenseed, and Vicus Therapeutics. He and/or his spouse have received research grants from Abbott Laboratories, Amgen, Bayer, Eli Lilly and Company, Exelixis, Genentech, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, sanofi-aventis, and Vicus Therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=84904423595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904423595&partnerID=8YFLogxK
U2 - 10.1177/1073274814021002s02
DO - 10.1177/1073274814021002s02
M3 - Article
C2 - 24681845
AN - SCOPUS:84904423595
SN - 1073-2748
VL - 21
SP - 5
EP - 16
JO - Cancer Control
JF - Cancer Control
IS - 2 SUPPL
ER -